Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial | Nature Cancer

|
By Alimu Dayimu, Stuart McIntosh, Beatrix Elsberger, Amit Agrawal, Steven Bell, Carlos Caldas, Karen Pinilla, Wendi Qian, Jean Abraham
| Nature
Abstract The use of progestogens in breast cancer has been controversial. Recent preclinical studies have shown that ligand-bound progesterone receptor interacts directly with the estrogen receptor (ER) and reprograms ER transcriptional activity. Progestogen cotreatment enhances the antitumor activity of antiestrogen therapy in mouse xenografts.
Open in Who Shared Issue with article?